Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRIS study of nirsevimab immunization in healthy infants
NL-OMON59371Phase 4Active, not recruiting
- Sponsor
- National Institute for Public Health and the Environment
- Start
- Aug 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of nirsevimab in respiratory syncytial virus disease (RSV) (2 arms), sponsored by National Institute for Public Health and the Environment. Primary endpoint: RSV-specific antibody levels at 12 months. Started Aug 2025; status: active, not recruiting.
02
Drugs
nirsevimab
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on NL-OMON59371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59371.